Therapeutic effect of modified Xiaoqinglong Decoction on cough-variant asthma and immunological functioning in children.

OBJECTIVE

To investigate the effect of modified Xiaoqinglong Decoction on cough variant asthma (CVA) and immunological functioning in children.

METHODS

In this is retrospective analysis, 122 children with CAV admitted to our hospital from Mar. 2021 to Mar. 2022 were divided into an observation group (n=61) and a control group (n=61) according to treatment methods. The control group received fluticasone propionate inhalation aerosol, and the observation group additionally received Xiaoqinglong Decoction. The therapeutic efficacy in the two groups was compared after 8 weeks of treatment. The comparison indictors included scores of daytime and nighttime cough, pulmonary function, fractional exhaled nitric oxide (FeNO), eosinophil count, inflammatory response (interleukin-4 (IL-4), tumor necrosis factor-α (TNF-α) and macrophage inflammatory protein ((MIP)-1α), immunoglobulin (Ig)) level and adverse reactions.

RESULTS

The overall response rate of children with CVA in the observation group was higher than that in the control group (). After treatment, the scores of daytime and nighttime cough in the observation group were lower than those in the control group (). The Forced Vital Capacity (FVC), peak expiratory flow (PEF) and FEV1 (Forced Expiratory Volume)/FVC of the observation group were higher than those in the control group (). The FeNO and eosinophil count in the observation group were lower than those in the control group (). The serum IL-4 was higher, while TNF-α and MIP-1α levels were lower in the observation group in the control group (). The serum IgA, IgG and IgM levels in the observation group were higher than those in the control group ().

CONCLUSION

The modified Xiaoqinglong Decoction has a conspicuous effect on children with CVA. It helps to reduce cough symptoms, improve pulmonary function, reduce inflammatory response and improve immunological functioning of children.